Oragenics, Inc.' Lead Antibiotic Effectively Kills Vancomycin-Resistant Bacteria

ALACHUA, FL--(MARKET WIRE)--Sep 5, 2007 -- Oragenics, Inc. (AMEX:ONI - News), a biotechnology development company, announced today laboratory results from a Tier 3 spectrum of activity study, conducted at an independent testing facility, which demonstrated that its lead antibiotic candidate, MU1140(TM), was effective at clinically relevant doses in killing pathogenic bacteria that are resistant to a variety of antibiotics, including all vancomycin-resistant strains of enterococci and Staphylococcus aureus in the Tier 3 Gram-positive bacterial panel. Vancomycin, approved by the FDA in 1958, is still considered the drug of "last resort" and is used for the treatment of serious, life-threatening infections which have not responded to other antibiotics.

Back to news